Anastrozole dispersed tablet formulation

A technology of anastrozole and dispersible tablets, applied in the field of pharmaceutical preparations, can solve the problems of decreased compliance, low bioavailability, low toxicity, etc., and achieve the effects of low production packaging cost, simple production process, and convenient administration
CN1634042AInactive Publication Date: 2005-07-06LUNAN PHARMA GROUP CORPORATION
0 Cites 7 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
LUNAN PHARMA GROUP CORPORATION
Publication Date
2005-07-06
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention belongs to medical technology, in particular to a dispersible tablet form of anastrozole. Through a large number of clinical investigations, we have overcome the technical prejudice that anastrozole does not need to be developed into dispersible tablets in the prior art, and obtained the present invention. Clinical experiments have confirmed that the adverse reactions of the present invention are significantly reduced, and the compliance of medication is significantly improved. Obtained unexpected clinical efficacy. It has the characteristics of low production cost, stable preparation, fast absorption and high bioavailability. The invention is suitable for treating advanced breast cancer of postmenopausal women, and provides a good therapeutic drug dosage form for breast cancer patients.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention belongs to the technology of pharmaceutical preparations, in particular to a clinical dosage form of anastrozole. Background technique

[0002] Cancer is a large class of diseases that seriously endanger human health. The mortality rate caused by tumors in my country ranks second among all causes, reaching 128.58 / 100,000 in 1995, and the incidence rate is on the rise.

[0003] Breast cancer is a common malignant tumor, ranking fifth in the incidence of cancer. In 1995, the mortality rate was 3.14 / 100,000, and the incidence rate increased every year. Anastrozole, developed by Zeneca, is a third-generation aromatase inhibitor for the treatment of advanced breast cancer in postmenopausal women. It is also effective for patients who have failed tamoxifen treatment; it has stronger effects and fewer side effects than the first-generation and second-generation aromatase inhibitors. Anastrozole has a highly specific selection effect, so it doe...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More